What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein found in human gastric juice. It was first isolated and studied by researchers at the University of Zagreb in Croatia in the early 1990s.
Unlike many other peptides that mimic hormones, BPC-157 appears to act through a distinct mechanism involving nitric oxide synthesis and angiogenesis — the formation of new blood vessels.
How Does BPC-157 Work?
The primary mechanisms behind BPC-157's regenerative effects include:
- Angiogenesis — BPC-157 upregulates VEGF (Vascular Endothelial Growth Factor), stimulating the growth of new capillaries into damaged tissue, which accelerates nutrient delivery and waste removal.
- Nitric Oxide Modulation — It influences the nitric oxide system, promoting vasodilation and tissue perfusion in injured areas.
- Tendon-to-Bone Healing — Studies show accelerated healing of tendon and ligament injuries through increased collagen synthesis and fibroblast migration.
- Gut Mucosal Protection — BPC-157 can heal intestinal permeability issues ("leaky gut"), reduce inflammation in the GI tract, and counteract NSAID-induced damage.
Research Overview
The majority of BPC-157 research has been conducted in rodent models. Key findings include:
- Accelerated healing of Achilles tendon rupture (Achilles tendon model, Zagreb group)
- Reduced inflammation in colitis and IBD models
- Protection against gastric ulcer formation
- Nerve regeneration in peripheral nerve damage models
- Counteracting corticosteroid-impaired wound healing
Human clinical trial data is limited, though anecdotal reports from athletes and biohackers are extensive. A Phase II trial for inflammatory bowel disease was completed, with results suggesting tolerability and some efficacy signals.
Common Uses
BPC-157 is most commonly used for:
- Tendon, ligament, and muscle injury recovery
- Post-surgery healing support
- Gut healing and IBD symptom management
- Joint pain and arthritis
Dosing and Administration
Typical research protocols use:
- Dose: 200–500 mcg per day
- Administration: Subcutaneous (SC) or intramuscular (IM) injection near the site of injury; oral capsules for gut-specific effects
- Cycle: Often used for 4–12 weeks depending on the injury
- Half-life: Estimated at approximately 4 hours
Injecting near the injury site (local injection) vs. systemically (remote site) may produce different outcomes — local injection appears to have stronger effects on musculoskeletal injuries.
Safety Profile
BPC-157 has a remarkably clean safety profile in animal studies — even at very high doses, no LD50 has been established. No significant adverse effects have been reported in human use, though the lack of large-scale clinical trials means long-term safety data is limited.
The primary concern raised by researchers is its pro-angiogenic activity — while beneficial for wound healing, stimulating blood vessel growth in the context of existing tumours could theoretically be problematic. This remains theoretical and has not been demonstrated experimentally.
Synergies
BPC-157 pairs exceptionally well with TB-500 (Thymosin Beta-4) — the two peptides are often combined into what the community calls the "Wolverine Stack." BPC-157 drives angiogenesis and collagen synthesis at the injury site, while TB-500 mobilises stem cells systemically and promotes actin polymerisation for tissue remodelling. Together, they address healing from complementary angles.